Navigation Links
PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Date:8/28/2007

iatives.

Based primarily on its strategic shift to focus on discovery and development of antibodies in oncology and select immunological diseases, PDL is conducting a thorough review of its organization, and anticipates a sizeable workforce reduction, to ensure that its structure and scope of operations are appropriately aligned with the new strategy.

Planned Sale of Commercial Operations

Given the change in strategic direction of the company and current timing of its pipeline, the company has determined that its commercial products and cardiovascular development programs are no longer a strategic fit.

As a result, the company has engaged Merrill Lynch & Co. to advise it on the sale of the rights to Cardene, Retavase, IV Busulfex and ularitide, and related assets, in one or more transactions. The company is seeking to retain staff in approximately 250 positions that support its commercial and cardiovascular products through the completion of the planned sale(s), but expects to eliminate these positions in connection with the sales of the company's commercial assets, which would be in addition to the workforce reduction anticipated in connection with aligning the organization to the company's new strategy. PDL has not finalized its plans for the optimal use of proceeds from the sale of these assets, but will provide updates on these and other financial options at the appropriate time. The company anticipates that its earnings will be significantly reduced in the near term following the sale of the marketed products, which generated $187.2 million in revenues in the 12 months ended June 30, 2007. Given the uncertain timing of and charges related to the planned transaction(s) and overall realignment, the company has suspended its financial guidance for 2007.

"Our marketed products have been an important component of the financial value of PDL, but they simply no longer fit with our new direction and timeline for commercialization of our in
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... iLab Solutions, the leader in core facility ... of Product Strategy. In this role, Michelle will work with ... guide in the development of iLab products. Her main goal ... benefit to the scientific community by offering the most advanced, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Global ... developing innovative information technology solutions for patients, physicians, ... care stakeholders, announced today the signing of a ... Food and Drug Administration (FDA). This initiative ...
(Date:1/14/2014)... January 14, 2014 Kerr Corporation, a leading ... and additional how-to information about dual arch impressions on its ... Dual Arch Impressions,” the blog entry serves up a list ... houses a step-by-step demonstration by Dr. David Little as he ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... equity stake in Zenotech Laboratories to 45%, GURGAON, ... Laboratories Limited (Zenotech) today announced the,signing of Definitive Agreements, ... its current 7% to 45% at a price of ... involves: (a) Purchase of shares from the existing ...
... Monday, October 8, at 2:15 ... p.m. ... Sciences Holdings, Inc. (Nasdaq: ADLS ), a biopharmaceutical,company engaged in the ... respiratory diseases and,cancer, is scheduled to present at the Natixis Bleichroeder Hidden ...
... 3 /PRNewswire-FirstCall/ - Biomira Inc. (Nasdaq: BIOM ... President and Chief,Executive Officer, is scheduled to present ... 2:45pm PDT/5:45pm EDT on Wednesday, October 10. ... and can be accessed at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BIOM&item_id=1 ...
Cached Biology Technology:Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology 2Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology 3Advanced Life Sciences to Present at Natixis Bleichroeder Hidden Gems Conference 2
(Date:4/23/2014)... allergies and other chronic inflammatory disorders among people of ... their reduced exposure to the microbes that thrive in ... The article, published in the journal Clinical & ... centers who have less access to green spaces may ... caused by immune system dysfunction. , When our immune ...
(Date:4/23/2014)... This news release is available in French and ... woman? Male or female? In humans and other mammals, the difference ... Y chromosome. It is present only in males, where the two ... chromosomes. Thus, the Y is ultimately responsible for all the morphological ... not always been the case. A very long time ago, the ...
(Date:4/23/2014)... ripping open a dinner roll, a fuel cell catalyst ... hydrogen molecule. Now researchers have captured a view of ... its hydrogen feast. The view confirms previous hypotheses and ... better for alternative energy uses. , This study is ... hydrogen halves end up in the structure of a ...
Breaking Biology News(10 mins):Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3Male or female? 2Male or female? 3Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4
... in Europe and United States are markedly underestimating the ... to prevent dangerous climate change because they work in ... from The University of Manchester, discovered that the lack ... has resulted in significant differences over who is responsible ...
... An international research team has identified a common gene ... atrial fibrillation. In their report in the journal ... that variations affecting a protein that may help control the ... is called lone atrial fibrillation (AF), a type seen in ...
... Blacksburg, Va. -- Math-based computer models are a powerful ... John Tyson, professor of biology at Virginia Tech, is ... and make decisions. "Cells receive information in the ... or radiation damage, for instance," Tyson said. "On the ...
Cached Biology News:Governments 'misjudging' scale of CO2 emissions 2Common gene variant may increase risk for a type of cardiac arrhythmia 2Biologists use mathematics to advance our understanding of health and disease 2Biologists use mathematics to advance our understanding of health and disease 3
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... (Ser843) Immunogen: ... encompassing the human, mouse, and rat ... Number: NM_153831 ... by immunoblot. ...
Biology Products: